Skip to main content

The ZUMA-8 Phase 1/2 Multicenter Study Evaluating KTE-X19 in Patients with Relapsed/Refractory CLL

Conference Correspondent - ASCO 2019 - Chronic Lymphocytic Leukemia

Despite treatment advances, chronic lymphocytic leukemia (CLL) remains largely incurable. First-line targeted therapy with ibrutinib produces durable remissions, but some patients discontinue treatment due to intolerance or disease progression.1 Prior research has indicated that autologous T-cells expressing a CD19-specific chimeric antigen receptor (CAR) with a CD28 costimulatory domain may be efficacious against CLL.2

KTE-X19 is an investigational, autologous, anti-CD19 CAR T-cell therapy that may offer longer durable remissions with manageable safety in patients with relapsed/refractory CLL. KTE-X19 is being evaluated in patients with relapsed/refractory CLL in the ZUMA-8 phase 1/2 multicenter study.

To be included in the study, adult patients were required to have relapsed/refractory CLL with ≥2 prior treatment regimens, disease progression with or intolerance to a Bruton’s tyrosine kinase inhibitor, Eastern Cooperative Oncology Group status 0 to 1, and adequate organ function. The phase 1 portion of the trial is expected to enroll 12 to 18 patients to assess dose-limiting toxicities. The phase 2 portion of the trial is expected to enroll approximately 60 patients to evaluate efficacy and safety. Patients will undergo leukapheresis followed by optional bridging therapy. Cyclophosphamide and fludarabine conditioning chemotherapy will be given on days –5, –4, and –3.

The primary end point is incidence of dose-limiting toxicities for phase 1 and Independent Review Committee–assessed objective response rate (ORR) per 2018 International Workshop on Chronic Lymphocytic Leukemia criteria for phase 2. Secondary end points in phase 2 include complete remission (CR) rate, investigator-assessed ORR, minimal residual disease (MRD) negativity rate, MRD-negative CR rate, duration of response, progression-free survival, overall survival, safety, and patient-reported outcomes. The ZUMA-8 study is currently enrolling patients at 30 sites in the United States and Europe.

Abstract TPS7566; Flinn I, et al.

References

  1. Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99:965-972.
  2. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709-2720.
Related Items
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Last modified: August 30, 2021